Location Directory

Clinical trials in Los Angeles, California

This page shows live ClinicalTrials.gov search results for Los Angeles, California, with direct links to official study records plus on-page filtering and sorting for broad location searches.

ClinicalTrials.gov public records Last synced May 21, 2026, 2:23 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

7183

Shown on this page

Local exact-city summaries

7183

Based on exact city/state matches in the local index.

Local exact-city recruiting

1376

Live official results below use the broader ClinicalTrials.gov location search.

The trial list below is retrieved from the live ClinicalTrials.gov search API for Los Angeles, California. Results on this page are currently sorted by Recently updated. Use the filter controls below to narrow by condition, treatment, sponsor, recruitment status, phase, study type, sex, or age.

Showing 1–12 of 7,183 matching trials in Los Angeles, CA.

Indexed local directory records.

The summary panels and records below use exact city/state matches from the local directory for Los Angeles, CA. Use the filters or full search link when you want broader live ClinicalTrials.gov location matching.

Top conditions in local exact-city summaries

Breast Cancer 192 HIV Infections 170 Prostate Cancer 117 Colorectal Cancer 114 Melanoma 100 Lung Cancer 96

Top sponsors in local exact-city summaries

National Cancer Institute (NCI) 392 University of Southern California 345 University of California, Los Angeles 326 Jonsson Comprehensive Cancer Center 288 Children's Oncology Group 186 Pfizer 178

Top therapies in local exact-city summaries

Pembrolizumab 175 Carboplatin 141 Cyclophosphamide 133 Nivolumab 125 Cisplatin 118 Paclitaxel 117

Indexed official records

Open in full search

Conditions: Essential Tremor
Interventions: Low Intensity Focused Ultrasound (LIFU); Device
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years to 90 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Post Traumatic Stress Disorder
Interventions: Placebo, TSND-201; Drug
Lead sponsor: Transcend Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 26
States / cities: Little Rock, Arkansas • La Jolla, California • Los Angeles, California + 23 more

Conditions: Brain Cancer, Central Nervous System Diseases, GBM, Glioblastoma (GBM), Glioblastoma Multiforme (GBM), Glioma, Newly Diagnosed Glioblastoma
Interventions: silevertinib in combination with temozolomide, temozolomide (TMZ); Drug
Lead sponsor: Black Diamond Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 162 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 7
States / cities: Springdale, Arkansas • Los Angeles, California • New Haven, Connecticut + 4 more

Conditions: Advanced Non-Small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung, Carcinoma, Non-Small-Cell Lung (NSCLC), Lung Cancer, Metastatic Non Small Cell Lung Cancer, Non-Small Cell Lung Cancer
Interventions: Chemotherapy Regimen 1, Chemotherapy Regimen 2, PF-08634404, Pembrolizumab; Drug · Biological
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 1,410 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 152
States / cities: Bullhead City, Arizona • Chandler, Arizona • Gilbert, Arizona + 124 more

Conditions: Respiratory Syncytial Virus Infections
Interventions: Placebo, S-337395; Drug
Lead sponsor: Shionogi; Industry
Eligibility: 18 Years and older
Enrollment: 192 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 33
States / cities: Los Angeles, California • Toluca Lake, California • Coral Gables, Florida + 19 more

Conditions: Amyotrophic Lateral Sclerosis (ALS)
Interventions: COYA 302, Placebo; Drug
Lead sponsor: Coya Therapeutics; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 21
States / cities: Phoenix, Arizona • Los Angeles, California • San Francisco, California + 17 more

Conditions: Locally Advanced Cervical Adenocarcinoma
Interventions: Biospecimen Collection, Brachytherapy, Carboplatin, Chest Radiography, Cisplatin, Computed Tomography, External Beam Radiation Therapy, Intensity-Modulated Radiation Therapy, Magnetic Resonance Imaging, Paclitaxel, Pembrolizumab, Positron Emission Tomography
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older · Female only
Enrollment: 336 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 243
States / cities: Birmingham, Alabama • Fayetteville, Arkansas • Little Rock, Arkansas + 193 more

Conditions: Endometrial Cancer, Malignant Solid Tumour
Interventions: Doxorubicin, Paclitaxel, Puxitatug Samrotecan; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 700 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 66
States / cities: Tucson, Arizona • La Jolla, California • Los Angeles, California + 57 more

Conditions: Chronic Low Back Pain (CLBP), Obesity, Overweight
Interventions: Placebo, Retatrutide; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 586 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 25
States / cities: Chandler, Arizona • Tucson, Arizona • Fountain Valley, California + 22 more

Conditions: Cachexia, Metastatic Pancreatic Ductal Adenocarcinoma
Interventions: placebo, ponsegromab; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 982 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 48
States / cities: Birmingham, Alabama • Bryant, Arkansas • Conway, Arkansas + 27 more

Conditions: Invasive Mold Infections
Interventions: Fosmanogepix IV infusion, Fosmanogepix oral tablet, Standard of care antifungal therapy; Drug
Lead sponsor: Basilea Pharmaceutica; Industry
Eligibility: 18 Years and older
Enrollment: 234 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 15
States / cities: Birmingham, Alabama • Duarte, California • Los Angeles, California + 11 more

Conditions: Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cancer
Interventions: Bevacizumab, Cemiplimab, Fianlimab, PLD, Sarilumab, Ubamatamab; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 220 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 21
States / cities: Birmingham, Alabama • La Jolla, California • Los Angeles, California + 17 more

Clinical trials in Los Angeles, California

Filter and sort this location

Top conditions in local exact-city summaries

Top sponsors in local exact-city summaries

Top therapies in local exact-city summaries

Indexed official records

Open Label Study for the Use of Low Intensity Focused Ultrasound for Essential Tremor

An Evaluation of the Safety and Efficacy of TSND-201 for the Treatment of PTSD (EMPOWER-1)

Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII

Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

A Study of S-337395 in Symptomatic Nonhospitalized Adults With Respiratory Syncytial Virus (RSV) Who Are at High Risk of Progression to Severe Disease

Study of COYA 302 for the Treatment of ALS

Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer

Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)

A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight and Chronic Low Back Pain

A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue

A Phase 3 Efficacy and Safety Study of Fosmanogepix for the Treatment of Adult Patients With Invasive Mold Infections.

Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer